Tourette Syndrome Treatment Guide for CBIT Medication Support and Research

Share this post:

LinkedIn
Facebook
X
Reddit
WhatsApp
Print

Tourette syndrome treatment may include education, watchful waiting, Comprehensive Behavioral Intervention for Tics, medication, school or work support and care for related conditions such as ADHD, OCD or anxiety. Many people with Tourette syndrome do not need active tic treatment when tics are mild and daily life is not affected. Treatment becomes more relevant when tics cause pain, injury, stress, school difficulty, work limits or social strain. The Centers for Disease Control and Prevention (CDC) states that Tourette syndrome has no cure, but behavioral treatment and medication can help manage tics when symptoms interfere with daily life.

Fast treatment answer

The best Tourette syndrome treatment plan depends on how tics affect your life. If your tics are mild, you may need education, monitoring and support from people around you. If your tics cause pain, injury, distress or daily limits, your clinician may discuss behavioral therapy, medication or both.

Comprehensive Behavioral Intervention for Tics, often called CBIT, is a key behavioral treatment. CBIT teaches you to notice tic urges, use a trained competing response and identify situations that make tics harder to manage. CDC describes CBIT as a behavioral therapy that can help many people with tic disorders manage tics better.

Medication can also help some people, especially when tics are severe or disruptive. Medication choices should be made with a qualified healthcare professional because side effects, other diagnoses and personal needs affect the plan. CDC notes that medications do not remove tics completely, but they may help some people in everyday life.

Treatment should also include related conditions. ADHD, OCD, anxiety, mood concerns, sleep problems and learning needs can affect your life as much as tics. A full care plan should look at the whole symptom pattern, not only the visible tic.

Treatment need based on pain, stress or daily limits

You may not need tic treatment just because tics are present. CDC states that many people with Tourette syndrome have tics that do not interfere with daily life and do not need treatment. Medication and behavioral treatment may help when tics cause pain or injury, interfere with school, work or social life or cause stress.

This impact based approach matters in real care. A child with mild blinking may need reassurance and teacher awareness only. A teen with repeated neck jerks and headaches may need active treatment. An adult with vocal tics that affect meetings may need behavioral care, workplace planning or medication review.

Treatment decisions should focus on the actual problem caused by the tic. You may want less pain, fewer interruptions, easier handwriting, less public anxiety, better sleep or safer driving. A useful plan can target those outcomes without promising that every tic will stop.

The American Academy of Neurology (AAN) guideline states that watchful waiting is acceptable when tics do not cause physical impairment, pain, emotional distress or social embarrassment. The same guideline says treatment should be individualized and based on collaboration among the patient, caregivers and the clinician.

When monitoring may be enough

Monitoring may be enough when tics are mild, infrequent, not painful and not causing school, work or social problems. You may still need education, a diagnosis when appropriate and a plan for follow up.

Monitoring can include short symptom notes, periodic visits and basic school or family education. For children, this may mean helping teachers avoid punishing tic symptoms. For adults, this may mean tracking pain, stress, sleep and work impact.

Monitoring should not become constant checking. Watching every movement can make symptoms feel bigger and can increase pressure. A brief weekly note is often enough unless symptoms change quickly or safety concerns appear.

You should move from monitoring to active care if tics become painful, embarrassing, disruptive, risky or emotionally distressing. You should also seek review if related symptoms such as ADHD, OCD, anxiety, depression or learning problems become more visible.

CBIT as a first behavioral option

CBIT is one of the main evidence based behavioral options for Tourette syndrome and chronic tic disorders. CDC states that CBIT can be effective for many people with tic disorders, including Tourette syndrome. It helps a person become aware of tics, practice a competing response and identify situations that can make tics worse.

CBIT is usually taught by a trained therapist. The therapist helps you choose one tic to work on, identify the urge that comes before it and practice a response that makes the tic harder to perform safely. The response is repeated until the urge decreases.

CBIT does not mean your tics are voluntary. CDC notes that the ability to manage tics through behavior change does not mean tics are done by choice. This point is important because many people with Tourette syndrome have already been blamed for symptoms they cannot fully control.

The AAN guideline recommends that clinicians consider CBIT when symptoms affect daily life. The AAN also states that CBIT is effective in children and adults and has no major side effects.

Habit reversal skills in plain language

Habit reversal is a core part of CBIT. It starts with awareness. You learn to notice what happens before the tic, where the urge is felt and when the tic tends to appear. This can include body sensations, settings, times of day or activities.

Next, you learn a competing response. This is a safe action that makes the tic harder to do. For a shoulder shrug tic, the response may involve holding the shoulders in a relaxed position. For a throat clearing tic, the response may involve a breathing pattern. The exact response should be selected by a trained provider.

You practice the competing response when the urge begins. The aim is to hold the response long enough for the urge to drop. This takes practice. It may feel awkward at first, and some tics may be easier to work on than others.

CBIT may also include function based changes. You and the therapist may identify settings that make tics worse and reduce pressure where possible. This can include seating changes, breaks, sleep routines, school planning or changes to high strain routines.

Who may be a good fit for CBIT

CBIT may be a good fit if you can notice at least some tic urges, practice skills between visits and work with a trained provider. Children, teens and adults may all benefit when the treatment matches their age and needs.

Younger children may need caregiver help. A parent can help practice skills without pressuring the child. The tone at home matters. Practice should feel supportive, not like punishment.

CBIT may need changes if you have ADHD, anxiety, learning differences, autism or severe tic intensity. You may need shorter practice periods, visual prompts, caregiver support or a slower pace.

CBIT access can be limited because trained providers are not available everywhere. CDC notes that healthcare providers need training to offer CBIT and that telehealth approaches may help with access.

Medication categories without dosing advice

Medication may be considered when tics are painful, unsafe, socially distressing or disruptive. A clinician may also consider medication when CBIT is unavailable, not enough by itself or not a good fit at the time.

Several medication categories may come up in clinical care. Some medicines are used mainly to reduce tics. Some may help tics and ADHD symptoms. Some are used for OCD, anxiety or mood symptoms that appear with Tourette syndrome. Your clinician should explain why a medicine is being considered, what benefit is expected and what side effects need monitoring.

CDC states that medications can be used to reduce severe or disruptive tics and can also be used for related conditions such as ADHD or OCD. CDC also notes that side effects from tic medications can include weight gain, stiff muscles, tiredness, restlessness and social withdrawal.

The AAN guideline says alpha 2 adrenergic agonists can improve symptoms of both tic disorders and ADHD in some patients. It also notes that antipsychotic medications may be prescribed when benefit is greater than risk, with discussion and monitoring of side effects.

Why medication decisions need clinical care

Medication decisions for Tourette syndrome should be made with a qualified healthcare professional. You should not start, stop or change medication on your own. This is especially important for children, teens, people with multiple diagnoses and people taking other medicines.

A clinician may ask about tic severity, pain, school or work effects, sleep, mood, attention, compulsive symptoms, other medications, medical history and family preferences. The safest choice depends on the whole picture.

Medication may reduce tic frequency or intensity, but it rarely removes all tics. The AAN states that treatments can reduce tic frequency and severity, but they rarely remove every tic.

Follow up is part of medication care. Your clinician may monitor sleepiness, blood pressure, weight, movement side effects, mood changes, attention changes, restlessness or lab findings depending on the medicine. If a medicine is not helping enough or side effects are difficult, the plan may change.

Treating ADHD alongside tics

ADHD is common in people with Tourette syndrome and can affect school, work, relationships and home life. CDC says people with Tourette syndrome commonly have related conditions, especially ADHD, anxiety and OCD. CDC also notes that treating these other conditions can sometimes help reduce tics.

If ADHD is present, a child may struggle with attention, impulse control, homework, class behavior or organization. An adult may struggle with deadlines, meetings, task switching or follow through. These problems may remain even when tics are mild.

The AAN guideline recommends evaluation for ADHD in people with tics. It also states that some treatments may help both ADHD and tics in certain patients.

Some families worry that ADHD medication will always worsen tics. This should be discussed with a clinician rather than assumed. The AAN clinician material notes that several ADHD treatments have been studied in children with tics and ADHD, including treatments assessed for ADHD benefit without tic worsening.

Treating OCD alongside tics

OCD can appear with Tourette syndrome and may need its own care plan. OCD symptoms can include intrusive thoughts, repeated checking, ordering, counting, washing, reassurance seeking or repeated actions linked to fear or discomfort.

Some compulsions can look like complex tics. A person may touch an object, repeat a phrase or redo an action. The inner reason can help separate the two. A tic is often linked to a body urge or sensation. A compulsion is often linked to fear, doubt or a need to reduce anxiety. Some people have both patterns.

The AAN guideline recommends evaluation for OCD in people with tics and appropriate OCD treatment when OCD is present. The AAN clinician material notes that cognitive behavioral therapy is considered a first line treatment for OCD symptoms in people with tic disorders.

If OCD is not treated, tic treatment alone may leave major daily problems in place. A child may spend hours repeating rituals. An adult may avoid tasks or settings because of intrusive thoughts. The care plan should address both tic symptoms and OCD symptoms when both are present.

Treating anxiety and mood concerns

Anxiety can increase tic awareness and make public settings harder. A person may worry about ticcing, then feel more pressure, then tic more. This cycle can affect school, work, social events, interviews and travel.

Mood concerns can also appear. A child may feel ashamed after being corrected repeatedly. A teen may withdraw from peers. An adult may avoid public situations. Depression, irritability or low confidence can become part of the daily burden.

The AAN guideline recommends evaluation for mood and anxiety disorders in people with tics because these conditions may also need treatment.

Care may include therapy, school planning, family education, anxiety treatment or medication when clinically appropriate. The aim is practical support for the person’s life, not pressure to hide all symptoms.

School support as part of care

School support is part of treatment when tics affect learning, peer relationships or classroom access. A child may need support even if no medication is used.

Tics can affect school in many ways. Vocal tics can interrupt quiet work or tests. Motor tics can affect handwriting, reading, lab tasks, sports or sitting still. Suppression during class can create fatigue and stronger tics at home. Bullying can increase distress.

Useful school supports may include the following.

  • Brief movement breaks
  • Permission to leave class when needed
  • Quiet testing space
  • Extra time when tics interrupt work
  • Typing instead of handwriting
  • Staff education
  • A plan for teasing or filming
  • A discreet signal between student and teacher

CDC states that training and educational resources can help parents and schools support children with Tourette syndrome. CDC also recommends including teachers, childcare providers, coaches, therapists and family members when developing the treatment plan.

School staff should avoid punishing tic symptoms. A tic related sound should not be treated as intentional disruption. A child should not have to prove symptoms by ticcing on demand.

Adult treatment planning

Adult Tourette treatment often focuses on work, relationships, driving, pain, sleep, public settings and related conditions. Some adults were diagnosed in childhood. Others spent years being told their symptoms were habits, stress or behavior problems.

An adult plan may include CBIT, medication, therapy for anxiety or OCD, ADHD treatment, workplace planning, pain care or sleep support. The right plan depends on how symptoms affect daily life.

Workplace support can include brief breaks, seating choice, meeting flexibility, written follow up after discussions, ergonomic changes or a private space during tic flares. Disclosure is personal. You may share only the information needed to receive support.

Adults should review pain carefully. Repeated neck, shoulder, jaw or back tics can cause muscle strain. A clinician may suggest tic treatment, physical therapy, ergonomic changes or pain care.

Adults should also review driving safety if tics affect eye closure, head movement, limb control or attention. A clinician can help assess risk and practical steps.

Severe tics and specialist care

Severe tics can cause injury, pain, falls, social isolation, school removal, work limits or unsafe situations. You should seek specialist care when tics are severe, complex, self injurious or difficult to manage with first line support.

A specialist may review diagnosis, tic patterns, related conditions, medication history, CBIT access, pain, sleep, safety and mental health. The care team may include neurology, psychiatry, psychology, behavioral therapy, occupational therapy, physical therapy, school staff or social work.

Severe tics sometimes require layered care. A person may need CBIT for tic skills, medication review for tic reduction, therapy for anxiety, school accommodations and pain care at the same time.

You should seek urgent care if tics cause serious injury, breathing difficulty, inability to eat or drink, sudden neurological changes, loss of awareness, severe depression or suicidal thoughts. If there is immediate danger, use local emergency services.

Deep brain stimulation as a rare specialist topic

Deep brain stimulation, known as DBS, is a rare treatment topic for Tourette syndrome. It involves implanted devices that deliver electrical stimulation to selected brain areas. DBS is considered only for severe cases after other treatment options have not provided enough help.

The AAN guideline states that adults with severe Tourette syndrome who are resistant to medical and behavioral therapy may benefit from DBS, but they should first be screened by a mental health professional and monitored during treatment.

DBS is not a routine treatment for most people with Tourette syndrome. It requires specialist evaluation, surgical risk review, psychiatric screening, long term programming and ongoing monitoring. It is usually discussed only in highly impairing adult cases.

If you are reading about DBS because symptoms are severe, bring the topic to a movement disorder neurologist or another specialist with tic disorder experience. Do not treat DBS as a standard next step after a short trial of care.

Research limits and emerging studies

Tourette syndrome research includes behavioral treatment access, medication safety, genetics, brain circuits, neurostimulation, digital care, pain, related conditions and long term outcomes. Better studies can help show which treatments work for which people and how care should change across childhood, adolescence and adulthood.

The AAN guideline is built around evidence review and clinical recommendations for people with Tourette syndrome and chronic tic disorders. The AAN guideline page says the recommendations address when people should pursue treatment and how patients and clinicians should choose among evidence based options. It was reaffirmed on April 7, 2025.

Psychedelic research is also active in regulated mental health settings. It may help scientists study brain networks, emotion processing and therapeutic models. Psilocybin is not an established Tourette syndrome treatment. The National Center for Complementary and Integrative Health (NCCIH) states that psilocybin has been studied in small and controlled settings for conditions such as depression, serious illness related distress and alcohol use disorder, while also listing safety risks and advising people not to delay medical care.

Any future tic related psychedelic study would need clear diagnostic criteria, validated tic measures, long term safety tracking and careful review of ADHD, OCD, anxiety and mood symptoms. Claims should stay tied to evidence.

Questions to ask a clinician

A strong treatment visit starts with clear questions. You can bring notes about tic type, duration, pain, school or work limits, related symptoms and past treatments.

You may ask the following.

  • Do the symptoms fit Tourette syndrome or another tic disorder
  • Do the tics need treatment now
  • Is watchful waiting reasonable
  • Is CBIT a good fit
  • Where can I find a trained CBIT provider
  • Should medication be considered
  • Which side effects need monitoring
  • Could one treatment help both tics and ADHD
  • Should OCD or anxiety be evaluated
  • What school or work support is appropriate
  • Are there safety concerns with driving, sports or tools
  • When should follow up happen

For a child, ask what teachers should do when tics happen. Ask what should be avoided. Ask for a short letter if school support is needed.

For an adult, ask about work documentation if symptoms affect meetings, calls, public roles or task performance. Ask about pain care if repeated tics strain the neck, jaw, shoulders or back.

How to prepare for a treatment visit

Before the visit, write down your main concerns. Focus on how tics affect daily life. A clinician needs to know more than the tic name. They need to know what the tic does to your body, your school, your job and your stress level.

You can track the following for one or two weeks.

  • Main motor tics
  • Main vocal tics
  • Pain or injury
  • Sleep changes
  • School or work problems
  • Social stress
  • Tic flares and possible triggers
  • ADHD symptoms
  • OCD symptoms
  • Anxiety or mood symptoms
  • Current medications and supplements

Short videos can help if the person with tics agrees. Tics may not appear during a short appointment. For children and teens, ask permission before recording and explain why it may help the clinician.

Bring past evaluations, school notes, therapy records, medication history and any side effect history. If symptoms affect school or work, bring examples of the task problem. “Hand tics make writing slow” is more useful than “tics are bad.”

Treatment choices for children

Treatment choices for children should account for age, tic severity, related conditions, family capacity, school setting and the child’s ability to participate.

Mild tics may need education and monitoring. A child should know they are not being punished for symptoms. Parents and teachers should avoid constant correction.

CBIT may help children who can notice urges and practice skills. Caregiver involvement can support practice, but parents should keep the tone calm. The child should not feel blamed when a tic happens.

Medication may be considered when tics cause pain, injury, major distress or daily limits. The clinician should discuss expected benefit, side effects and monitoring. The child’s school and home needs should be part of the plan.

Related conditions should be evaluated. ADHD can affect school function. OCD can consume time and cause distress. Anxiety can increase avoidance. Learning issues can make classroom tasks harder. A tic treatment plan that ignores these concerns may leave the child struggling.

Treatment choices for teens

Teen treatment planning should include privacy, autonomy and social pressure. Teens may care deeply about who knows, what gets written in school documents and how visible support will be.

CBIT can be helpful when the teen is motivated and able to practice. A teen may prefer discreet skills that can be used in public. The therapist can work with the teen to choose tics that affect daily life most.

Medication discussions should include the teen when possible. Teens may worry about sleepiness, weight change, mood effects, attention or stigma. Honest discussion improves follow through.

School planning should account for peer issues, testing, filming, sports and driving. If tics affect vision, head movement, arms or legs, driving safety should be discussed with a clinician.

Mental health support may be needed if tics lead to avoidance, shame, bullying, depression or anxiety. The teen should have a private space to discuss these issues with the care team.

Treatment choices for adults

Adults may seek treatment after years of symptoms or after a flare that affects work, parenting, driving or pain. Some adults are newly diagnosed because symptoms were misunderstood earlier in life.

Adult treatment may include CBIT, medication, therapy for anxiety or OCD, ADHD care, workplace planning and pain support. The plan should match your daily roles and responsibilities.

If you have a public facing job, vocal tics may need a disclosure plan or meeting plan. If you do fine motor work, hand tics may need task changes. If you have neck tics, pain treatment may be a priority.

Adults should review medication side effects carefully, especially when other medications, medical conditions or pregnancy planning are present. A clinician can help weigh benefits and risks.

Support for families and caregivers

Family support can reduce stress around Tourette syndrome. Tics should not be treated as misbehavior. A child may be able to delay symptoms briefly, but that does not mean symptoms are fully voluntary.

Caregivers can help by learning the tic pattern, reducing repeated correction, supporting treatment practice and talking with school staff when needed. They can also watch for pain, bullying, anxiety, depression, ADHD symptoms and OCD symptoms.

Family members may need their own education. Siblings may feel annoyed by vocal tics or confused by different rules. A calm explanation can help them respond with respect.

Caregivers should also protect the child’s privacy. Not every relative, teacher or peer needs full details. Share only what helps the child receive support and safety.

What treatment can and cannot do

Treatment can reduce tic frequency, tic intensity, pain, distress or interference with daily life. Treatment can also improve support around school, work, family and social settings.

Treatment may not remove every tic. The AAN states that treatments rarely remove all tics. This point can help set realistic expectations.

Care plans can change. A child who needs monitoring at age seven may need CBIT at age ten. A teen who needed medication during a severe period may later need a different plan. An adult may return to care when work demands or pain changes.

The best plan is the one that matches your symptoms, age, related conditions, safety needs and daily life.

Reliable resources and next steps

Reliable Tourette syndrome treatment information should come from public health agencies, neurology guidelines, qualified clinicians, academic medical literature and tic disorder specialists. CDC and AAN are useful starting points because they explain treatment need, CBIT, medication and related conditions in plain clinical terms.

Your next step depends on symptom impact. If tics are mild and not disruptive, ask your clinician about monitoring and education. If tics cause pain, injury, school issues, work problems, distress or social strain, ask about CBIT, medication options and related condition screening.

If ADHD, OCD, anxiety, mood symptoms, sleep problems or learning needs are present, ask for those to be addressed in the same care plan. Treating related conditions can improve daily function and may reduce tic burden for some people.

If symptoms are severe, self injurious or resistant to initial care, ask for referral to a specialist with tic disorder experience. Severe cases may need a team based plan and careful follow up.

Rose Hill research note

As you review Tourette syndrome treatment, CBIT, medication options and future research questions, we at Rose Hill Life Sciences approach this topic through science led education. Our work focuses on psychedelic research, production and study of Psilocybe cubensis, the intersection of science and therapeutic integration and our Massachusetts research work, while Tourette syndrome treatment decisions should remain with qualified healthcare professionals.

Conclusion

You can start with the level of care that fits the impact of your tics. Mild symptoms may need education and monitoring. Tics that cause pain, injury, distress or daily limits may need CBIT, medication, school or work support and care for related conditions.

CBIT is a key behavioral option with evidence for children and adults. Medication may help some people, but it requires clinical monitoring. ADHD, OCD, anxiety, mood symptoms and learning needs should be assessed because they can shape daily life and treatment priorities.

A good treatment plan should answer practical questions. What symptom is causing the biggest problem? What support can reduce harm now? What treatment fits your age and needs? What follow up is needed if symptoms change?

Disclaimer: The information in this article is for educational and informational purposes only and does not constitute medical advice.

You May Also Like

Adam Goodman

Advisor

Adam is a seasoned entrepreneur with a wealth of experience in spearheading real estate development and management endeavors. His focus primarily lies in land development, where he orchestrates the intricate tapestry of planning and zoning entitlements, while meticulously overseeing all facets of engineering and architectural design, leasing, construction, and financing.

With a national reach spanning 23 states and encompassing over 250 properties, totaling more than 6 million square feet, Adam’s proficiency in navigating the complexities of the industry is evident.

Beyond real estate, Adam’s endeavors extend into the realm of alternative investments, boasting successful ventures in healthcare, professional sports franchises, financial services, diverse agricultural platforms, and the stewardship of local restaurants.

 

Rotem Petranker, PhD, Psychology

Psychedelic Researcher

Rotem Petranker is a psychedelics researcher with a particular emphasis on microdosing, therapy, research methods and research ethics. He earned his BSc from the University of Toronto, his Master’s degree from York University, and his PhD from McMaster University.

As part of my research, I have gained extensive expertise in navigating the regulatory landscapes of Health Canada and the FDA and a strong background in designing rigorous clinical trial research methodologies. 

I founded the Canadian Centre for Psychedelic Science in 2018, established the Psychedelic Science Research Program at the University of Toronto in 2019, and, more recently, ran the largest clinical trial to date on the effectiveness of microdosing psilocybin for Major Depressive Disorders. I have published many papers on microdosing, including some of the largest samples in the literature and some that have set standards for performing psychedelic research.

Kevin Bourke

Chief Commercial Officer

Kevin Bourke is a dynamic executive and strategic planner whose career spans over two decades of crafting and elevating world-class Jamaican brands and transformational experiences on the global stage. With a keen understanding of culture, identity, and international markets, he has played a pivotal role in shaping some of Jamaica’s most iconic names — including Appleton Estate Rum, Chris Blackwell’s Rum, and Usain Bolt’s Tracks & Records — bringing them from local roots to international acclaim. His leadership and vision have also been instrumental in major cultural movements such as Fiction and the internationally recognized TmrwTday Wellness Festival.

An innovator at heart, Mr. Bourke seamlessly blends brand strategy with deep cultural resonance. His ability to connect with diverse audiences has established these brands not only as commercial successes but as symbolic ambassadors of Jamaican excellence, fortifying the island’s influence in beverage, music, lifestyle, and experiential sectors.

In recent years, Kevin has steered his strategic acumen toward the cutting-edge psilocybin and wellness industry, becoming a co-founder and Chief Marketing and Branding Officer of Rose Hill, Jamaica’s leading cultivator, exporter, and innovator of psilocybin products and experiences. Through ventures like ONE Retreats, he has helped craft safe, guided psychedelic-assisted healing programs that attract participants from around the world seeking deep personal transformation, including military veterans and international wellness seekers.

Kevin’s impact extends beyond business into industry shaping and policy, as he sits on the Jamaica Psilocybin Mushroom Industry Technical Committee (under the Bureau of Standards) — a pivotal body that is formalizing guidelines and regulatory standards for the emerging legal psilocybin sector in Jamaica. His presence on this committee underscores his leadership role in ensuring the industry’s integrity, safety, and sustainable growth.

Highly regarded for his extensive network throughout Jamaica and internationally, Kevin remains passionately committed to advancing ethical, high-integrity product development and customer-centric experiences at every level. His dedication is driven not only by professional achievement but by a deep vision for human well-being, cultural celebration, and the global evolution of plant-based healing.

Jama Pitman

Regulatory Strategy

Jama Pitman is a seasoned biopharmaceutical executive with extensive expertise in global drug development and commercialization. With over two decades of experience, she has contributed to the development of groundbreaking therapies across oncology, rare diseases, and antivirals. As a strategic leader, she has successfully transitioned companies from private to public markets, navigated complex M&A transactions, and driven innovative drug approvals.

Jama has held executive roles in leading organizations, including Deciphera Pharmaceuticals, where she played a pivotal role in scaling operations from a small, privately held biotech company to a global, multi-product company acquired for $2.4 billion. She brings exceptional skills in regulatory affairs, portfolio management, quality assurance, and clinical operations, longside a proven track record of fostering inclusivity and mentorship within her teams.

Currently, as the founder of JP BioPharma Consulting, Jama advises biopharma and tech companies on accelerating drug development and achieving corporate goals. Her collaborative and forward-thinking approach aligns seamlessly with Rose Hill’s mission to advance transformative therapies in mental health and beyond.

Education: B.Sc. in Microbiology, University of New Hampshire.

Notable Achievements: Contributed to the development of multiple FDA-approved therapies, including QINLOCK® for gastrointestinal stromal tumors.

Domenic Suppa

Chief Operating Officer

Domenic is co-founder and the Operations Chief of Rose Hill Health Holdings.

He has been working as a Cannabis technology and operations veteran with more than 11 years’ experience as a senior executive in an operationally complex, and highly regulated industry.

His introduction and entrance into the Cannabis sector started in 2010 with a seed investment into a Denver-based vertically integrated cannabis company called, Evolab. He served as C.O.O. for 5 years from 2013-2018, through the eventual acquisition by Harvest Health and Recreation (HARV: CSE).

Domenic moved on to be acting COO of the manufacturing division for Supreme Cannabis (CSE: FIRE) and supported the acquisition of BLISSCO (CSE: BLISS, a BC-based cannabis manufacturer). Domenic has worked with high-profile national cannabis brands including KKE, and Monogram, and retail brands in MA Native Sun, Terps, and Tilt. Domenic is a proven leader and team builder; his previous experiences have all been with early-stage and growth equity enterprises.

He has refined and evolved his leadership roles, including his team-building skills. He is a value creator. Domenic is a firm believer in training and continuous development. He excels in employing practices, tools, and methodologies designed to achieve maximum process efficiency while minimizing waste and delays.

 

Burton J. Tabaac

Clinical Development

Dr. Burton J. Tabaac, MD, FAHA, brings a wealth of expertise in neurology and stroke rehabilitation to Rose Hill. As an Associate Professor and Section Chief of Neurology at The University of Nevada’s Reno School of Medicine, and Medical Director of Stroke at Carson Tahoe Health, Dr. Tabaac has been at the forefront of innovative neurological treatments.

A graduate of the prestigious cerebrovascular neurology fellowship program at The Johns Hopkins University Hospital, Dr. Tabaac’s accolades include being a three-time recipient of The Arnold P. Gold Foundation’s Humanism and Excellence in Teaching Award and induction into the Alpha Omega Alpha Honor Medical Society.

He recently published an eight-part paper in the American Journal of Therapeutics reviewing psychedelics as therapeutics for primary care clinicians. Dr. Tabaac’s groundbreaking research focuses on the application of psychedelics in brain injury and stroke rehabilitation.

Dr. Tabaac was recently appointed by the Governor of Nevada to serve as a member of the state’s Psychedelic Medicines Working Group, which provides expertise and testimony relating to the therapeutic use of entheogens.

As the host of The Zero Hour Podcast, he engages with leading experts in psychedelic research. His commitment to advancing the field was further highlighted in his 2022 TEDx talk at UCLA, “Mental Health Meets Psychedelics.”

“Joining Rose Hill’s advisory team presents an exciting opportunity to further explore the potential of psilocybin in neurological recovery,” said Dr. Tabaac.

“The company’s commitment to ethical cultivation and research aligns perfectly with my vision for advancing patient care through innovative therapies. I’m eager to bring my expertise to Rose Hill and contribute to the evolving landscape of psychedelic medicine.”

Charles Lazarus

Chief Executive Office

Mr. Lazarus boasts over 16 years of extensive expertise in psilocybin and cannabis, focusing on genetic development, cultivation, extraction, and operations logistics. Notably, he recently achieved a milestone by cultivating and delivering the largest legal shipment of premium psilocybin globally.

As an accomplished owner/operator, Mr. Lazarus has successfully managed multiple farming and harvesting businesses, earning commendations for his unwavering commitment to quality and impressive output volumes. Since 2015, he has been actively involved in producing proprietary psilocybin genetics and cultivation solutions tailored for the Jamaican market and large research and development clients.

His contributions span various aspects, including genetic development, cultivation, extraction, harvest, and logistics. Additionally, Mr. Lazarus owned and operated Island Fresh Ltd., a venture that played a pivotal role in exporting fresh fruit, ground provisions, and promoting brand Jamaica to the English market. Under his leadership, Island Fresh Ltd. achieved the highest volume from Jamaica for three consecutive years.

Mr. Lazarus’s extensive experience also includes serving as the Harvest Manager for cannabis grow operations in California from 2013 to 2017, further solidifying his comprehensive knowledge in the cannabis industry.